Malaysiakini
ENBM中文TA
Sign In
Subscribe
  • LifetimeACTIVEINACTIVEEXPIRED
  • Registered on:Renews on:Expires on:
    ACTIVEINACTIVEEXPIRED
  • Subscribe
  • Renew
  • Extend Subscription
  • Settings
  • Contact Support
  • Sign Out
  • Latest
  • Videos
  • Opinions
  • Yoursay
  • Featured
  • Kini News Lab
  • KiniGuide
  • Sustainability
  • Events
  • Collab Content
  • TopTech
  • Our Team
  • Privacy Policy
  • Terms of Service
  • Advertise with us
  • Careers
  • Email
  • WhatsApp
  • File a complaint
  • Address
Malaysiakini
user
Sign In
Subscribe
ENBM中文TA
  • Latest
  • Videos
  • Opinions
  • Yoursay
  • Featured
  • Kini News Lab
  • KiniGuide
  • Sustainability
  • Events
  • Collab Content
  • TopTech
  • Our Team
  • Privacy Policy
  • Terms of Service
  • Advertise with us
  • Careers
  • Email
  • WhatsApp
  • File a complaint
  • Address
ENBM中文TA

      ANNOUNCEMENT

      He was the sole candidate proposed for the post during a state committee meeting.

      He was the sole candidate proposed for the post during a state committee meeting.

      India's drugs experts approve AstraZeneca, local Covid-19 vaccines
      Malaysiakini
      News
      India's drugs experts approve AstraZeneca, local Covid-19 vaccines

      India's drugs experts approve AstraZeneca, local Covid-19 vaccines

      ReutersPublished: Jan 2, 2021 11:55 PM | Updated: Jan 3, 2021 2:57 AM

      Experts at India’s drugs regulator have recommended for emergency use two coronavirus vaccines, one developed by AstraZeneca and Oxford University and the other backed by a state-run institute, the government said on Saturday.

      A government minister said earlier the AstraZeneca/Oxford vaccine had been given the green light on Friday, paving the way for a huge immunisation campaign in the world’s second-most populous country...

      Explainer: What we know about China-made vaccines

      Explainer: What we know about China-made vaccines

      Only two-thirds willing to receive Covid-19 vaccine, short of herd-immunity target

      Only two-thirds willing to receive Covid-19 vaccine, short of herd-immunity target

      Explainer: How does AstraZeneca's vaccine compare with Pfizer-BioNTech?

      Explainer: How does AstraZeneca's vaccine compare with Pfizer-BioNTech?

      WHO marks year since Covid-19 began, urges fair vaccine distribution

      WHO marks year since Covid-19 began, urges fair vaccine distribution

      Sinopharm's Covid-19 vaccine 79pct effective, seeks approval in China

      Sinopharm's Covid-19 vaccine 79pct effective, seeks approval in China

      Britain first to approve AstraZeneca/Oxford Covid-19 vaccine

      Britain first to approve AstraZeneca/Oxford Covid-19 vaccine

      Singapore begins rollout of Pfizer's Covid-19 vaccine with healthcare workers

      Singapore begins rollout of Pfizer's Covid-19 vaccine with healthcare workers

      • comments0
      • facebook
      • whatsapp
      • x
      • comments0
      • facebook
      • whatsapp
      • x
      Related reports7

      Explainer: What we know about China-made vaccines

      01-01-2021

      Only two-thirds willing to receive Covid-19 vaccine, short of herd-immunity target

      01-01-2021

      Explainer: How does AstraZeneca's vaccine compare with Pfizer-BioNTech?

      31-12-2020

      WHO marks year since Covid-19 began, urges fair vaccine distribution

      30-12-2020

      Sinopharm's Covid-19 vaccine 79pct effective, seeks approval in China

      30-12-2020

      Britain first to approve AstraZeneca/Oxford Covid-19 vaccine

      30-12-2020

      Singapore begins rollout of Pfizer's Covid-19 vaccine with healthcare workers

      30-12-2020
      View Comments0

      Comments0

      By posting a comment, you agree to our Commenting Terms and Conditions as stipulated in full here.

      Do's and don'ts when posting comments in Malaysiakini

      TERMS & CONDITIONS

      Foul language, profanity, vulgarity, slanderous, personal attack, threatening, sexually-orientated comments or the use of any method of communication that may violate any law or create needless unpleasantness will not be tolerated. Antisocial behaviour such as "spamming" and "trolling" will be suspended. Violators run the risk of also being blocked permanently.

      REPORT VIOLATORS

      Please use the report feature that is available below each comment to flag offending comments for our moderators to take action. Do not take matters in your own hands to avoid unpleasant and unnecessary exchanges that may result in your own suspension or ban.

      NOTICE

      Our commenting system is still under development. We have taken note of feedback provided.

      Subscriber-only space:

      Are you a subscriber?

      Sign In

      Not yet a subscriber?

      Subscribe

      3200 characters remaining

      Pending comments0

      Are you sure you want to delete this comment?

      This action cannot be undone.

      Report this comment

      500 characters remaining
      mk-logo
      • whatsapp
      • telegram
      • youtube
      • facebook
      • x
      • instagram
      • tiktok
      • linkedin
      • About Us
      • Our Team
      • Privacy Policy
      • Terms of Service
      • Advertise with Us
      • Careers
      • Archive
      • Digital Network
      • KiniTV
      • FG Media
      • RSS Feeds
      • News
      • Opinion
      • Letters
      Contact Editorial
      envelopeeditor@malaysiakini.com
      Contact Subscription/Tech Support
      telephone+6017-323 0707
      envelopesubscribe@malaysiakini.com
      • Advertising
      • advertise@malaysiakini.com
      • advertise@fgmedia.my
      Mkini Dotcom Sdn Bhd
      (199901014818 / 489718-U)No. 9, Jalan 51/205A, Off Jalan Tandang, 46050 Petaling Jaya, Selangor
      Contact Editorial
      envelopeeditor@malaysiakini.com
      Contact Subscription/Tech Support
      telephone+603-7770 0017
      envelopesubscribe@malaysiakini.com
      @Kini
      No. 9, Jalan 51/205A, Off Jalan Tandang, 46050 Petaling Jaya, Selangor